Literature DB >> 28138822

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Marwan H Adwan1.   

Abstract

PURPOSE OF THE REVIEW: The purpose of the review is to summarise the various drugs used in rheumatology practice implicated in the causation of DRESS syndrome. RECENT
FINDINGS: The most commonly reported drugs are allopurinol, sulfasalazine and minocycline, which pose a very high risk for DRESS syndrome development, followed by strontium ranelate and dapsone. Other, less commonly reported, drugs include leflunomide, hydroxychloroquine, non-steroidal anti-inflammatory drugs, febuxostat, bosentan and solcitinib. Reaction to some drugs is strongly associated with certain HLA alleles, which may be used to screen patients at risk of serious toxicity. DRESS syndrome is a serious reaction to many drugs used in rheumatic diseases, with a potentially fatal outcome and needs to be considered in any patient started on these medications who presents with a rash, fever and eosinophilia, sometimes with internal organ involvement.

Entities:  

Keywords:  Allopurinol; DRESS syndrome; Eosinophilia; Hypersensitivity; Idiosynchratic; Minocycline; Sulfasalazine; Toxicity

Mesh:

Substances:

Year:  2017        PMID: 28138822     DOI: 10.1007/s11926-017-0626-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  79 in total

1.  Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence.

Authors:  Deng-Chi Yang; Chia-Ming Chang
Journal:  J Am Geriatr Soc       Date:  2010-10       Impact factor: 5.562

2.  Cyclosporine Treatment of Drug-Induced Hypersensitivity Syndrome.

Authors:  Mark G Kirchhof; Aaron Wong; Jan P Dutz
Journal:  JAMA Dermatol       Date:  2016-11-01       Impact factor: 10.282

3.  Severe DRESS syndrome managed with therapeutic plasma exchange.

Authors:  Thomas Alexander; Edward Iglesia; Yara Park; Daniel Duncan; David Peden; Saira Sheikh; Maria Ferris
Journal:  Pediatrics       Date:  2013-02-18       Impact factor: 7.124

4.  T cell involvement in cutaneous drug eruptions.

Authors:  Y Hari; K Frutig-Schnyder; M Hurni; N Yawalkar; M P Zanni; B Schnyder; A Kappeler; S von Greyerz; L R Braathen; W J Pichler
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

Review 5.  Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

Authors:  H Bocquet; M Bagot; J C Roujeau
Journal:  Semin Cutan Med Surg       Date:  1996-12

Review 6.  Dapsone and sulfones in dermatology: overview and update.

Authors:  Y I Zhu; M J Stiller
Journal:  J Am Acad Dermatol       Date:  2001-09       Impact factor: 11.527

7.  A 6-month prospective survey of cutaneous drug reactions in a hospital setting.

Authors:  F Fiszenson-Albala; V Auzerie; E Mahe; R Farinotti; C Durand-Stocco; B Crickx; V Descamps
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

8.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors:  H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Arthritis Rheum       Date:  2008-11-15

Review 9.  Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors.

Authors:  Werner J Pichler; Jacqueline Adam; Stephen Watkins; Natascha Wuillemin; James Yun; Daniel Yerly
Journal:  Int Arch Allergy Immunol       Date:  2015-11-03       Impact factor: 2.749

Review 10.  Digging up the human genome: current progress in deciphering adverse drug reactions.

Authors:  Shih-Chi Su; Wen-Hung Chung; Shuen-Iu Hung
Journal:  Biomed Res Int       Date:  2014-03-10       Impact factor: 3.411

View more
  4 in total

Review 1.  Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.

Authors:  Linda J Zhu; Anne Y Liu; Priscilla H Wong; Anna Chen Arroyo
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-29       Impact factor: 10.817

2.  The significance of the hemalexin C1q, RBP, and urinary NAG levels in the diagnosis and prognosis of children with purpura nephritis.

Authors:  Huiwu Zhang; Xiuli Li; Haiping Xu; Fang Ran; Guoxia Zhao
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  DRESS syndrome in response to Denosumab: First documented case report.

Authors:  Mariam Al-Attar; Maria De Santis; Marco Massarotti
Journal:  Bone Rep       Date:  2019-12-13

Review 4.  Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Authors:  Lisa K Stamp; Hamish Farquhar; Huai Leng Pisaniello; Ana B Vargas-Santos; Mark Fisher; David B Mount; Hyon K Choi; Robert Terkeltaub; Catherine L Hill; Angelo L Gaffo
Journal:  Nat Rev Rheumatol       Date:  2021-07-30       Impact factor: 20.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.